Fig 2. Effect of genotype on change in strength over 12 months of the LACE trial.

Proportionate strength was determined by dividing MVC at month 12 by MVC at baseline allowing us to combine data from men and women in the study. (A) Individuals with the DD genotype had a higher proportionate strength at month 12 than individuals with the II/ID genotype (Mann-Whitney U test). (B and C) Comparison of the baseline and 12-month MVC showed that the DD individuals (B) increased in strength over the course of the trial (p = 0.003 Wilcoxon-signed rank test) whereas there was no change in strength in the II/ID individuals (C). There was no effect of perindopril on proportionate strength in either the DD or II/ID genotypes (D).